In vitro stability of arsenic trioxide-liposome encapsulates for acute promyelocytic leukemia treatment

Add time:08/31/2019    Source:sciencedirect.com

In this work, we investigated the stability of arsenic trioxide (ATO) used in leukemia treatment, encapsulated with nanoliposome, with the aid of ultrasound treatment. Stability studies of As species were followed by liquid chromatography-inductively coupled plasma mass spectrometry (LC-ICP-MS), allowing for the detection of the conversion of low amounts of As(III) to As(V) or the formation of other As species. The influence of storage temperature and time on ATO was evaluated. Low amounts of As(III) to As(V) conversions were observed when the As encapsulated with nanoliposome was incubated at 25 °C and 40 °C. However, As(III) was stable if the solution was maintained at 5 °C, even after 90 days. No formation of other As species was observed, indicating good stability of the encapsulated ATO. Next step of the work will focus on spray drying of ATO nanoliposomes-encapsuleted with the aim of long term stability of As.

We also recommend Trading Suppliers and Manufacturers of titanium trioxide (cas 1344-55-4). Pls Click Website Link as below: cas 1344-55-4 suppliers

Prev:Silver nanoparticles decorated titanium dioxide-tungsten trioxide nanotube films with enhanced visible light photo catalytic activity
Next:Titanium dioxide/tungsten trioxide nanoarrays film for high electrochromic performance)